Cardiac biomarkers market size is expected to record 12.8% CAGR from 2023 to 2032. The rising prevalence of cardiovascular diseases worldwide, coupled with an aging population, has spurred the need for advanced diagnostic tools. According to a new report from the World Heart Federation (WHF), nearly 20.5 million deaths happened due to cardiovascular (CVD) in 2021.
The advent of cutting-edge technologies and the growing emphasis on early detection have elevated the importance of cardiac biomarkers in clinical practice. These biomarkers, ranging from proteins to genetic markers, are becoming indispensable tools for healthcare professionals in predicting, diagnosing, and managing cardiovascular conditions, thus reshaping the landscape of cardiac care.